185 related articles for article (PubMed ID: 36145648)
21. Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3.
Ansideri F; Macedo JT; Eitel M; El-Gokha A; Zinad DS; Scarpellini C; Kudolo M; Schollmeyer D; Boeckler FM; Blaum BS; Laufer SA; Koch P
ACS Omega; 2018 Jul; 3(7):7809-7831. PubMed ID: 30087925
[TBL] [Abstract][Full Text] [Related]
22. Colocalization and Interaction Study of Neuronal JNK3, JIP1, and β-Arrestin2 Together with PSD95.
Musi CA; Marchini G; Giani A; Tomaselli G; Priori EC; Colnaghi L; Borsello T
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456931
[TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.
Zheng K; Iqbal S; Hernandez P; Park H; LoGrasso PV; Feng Y
J Med Chem; 2014 Dec; 57(23):10013-30. PubMed ID: 25393557
[TBL] [Abstract][Full Text] [Related]
24. Jnk2 deficiency increases the rate of glaucomatous neurodegeneration in ocular hypertensive DBA/2J mice.
Harder JM; Williams PA; Soto I; Foxworth NE; Fernandes KA; Freeburg NF; Libby RT; John SWM
Cell Death Dis; 2018 Jun; 9(6):705. PubMed ID: 29899326
[TBL] [Abstract][Full Text] [Related]
25. K252a prevents nigral dopaminergic cell death induced by 6-hydroxydopamine through inhibition of both mixed-lineage kinase 3/c-Jun NH2-terminal kinase 3 (JNK3) and apoptosis-inducing kinase 1/JNK3 signaling pathways.
Pan J; Wang G; Yang HQ; Hong Z; Xiao Q; Ren RJ; Zhou HY; Bai L; Chen SD
Mol Pharmacol; 2007 Dec; 72(6):1607-18. PubMed ID: 17855652
[TBL] [Abstract][Full Text] [Related]
26. Rational modification, synthesis and biological evaluation of 3,4-dihydroquinoxalin-2(1H)-one derivatives as potent and selective c-Jun N-terminal kinase 3 (JNK3) inhibitors.
Dou X; Huang H; Jiang L; Zhu G; Jin H; Jiao N; Zhang L; Liu Z; Zhang L
Eur J Med Chem; 2020 Sep; 201():112445. PubMed ID: 32603981
[TBL] [Abstract][Full Text] [Related]
27. JNK3 as a therapeutic target for neurodegenerative diseases.
Antoniou X; Falconi M; Di Marino D; Borsello T
J Alzheimers Dis; 2011; 24(4):633-42. PubMed ID: 21321401
[TBL] [Abstract][Full Text] [Related]
28. Palmitoylation couples the kinases DLK and JNK3 to facilitate prodegenerative axon-to-soma signaling.
Niu J; Holland SM; Ketschek A; Collura KM; Hesketh NL; Hayashi T; Gallo G; Thomas GM
Sci Signal; 2022 Mar; 15(727):eabh2674. PubMed ID: 35349303
[TBL] [Abstract][Full Text] [Related]
29. Targeting JNK3 for the treatment of neurodegenerative disorders.
Resnick L; Fennell M
Drug Discov Today; 2004 Nov; 9(21):932-9. PubMed ID: 15501728
[TBL] [Abstract][Full Text] [Related]
30. JNK3 contributes to c-Jun activation and apoptosis but not oxidative stress in nerve growth factor-deprived sympathetic neurons.
Bruckner SR; Tammariello SP; Kuan CY; Flavell RA; Rakic P; Estus S
J Neurochem; 2001 Jul; 78(2):298-303. PubMed ID: 11461965
[TBL] [Abstract][Full Text] [Related]
31. Neuroprotective Effects of the Absence of JNK1 or JNK3 Isoforms on Kainic Acid-Induced Temporal Lobe Epilepsy-Like Symptoms.
de Lemos L; Junyent F; Camins A; Castro-Torres RD; Folch J; Olloquequi J; Beas-Zarate C; Verdaguer E; Auladell C
Mol Neurobiol; 2018 May; 55(5):4437-4452. PubMed ID: 28664455
[TBL] [Abstract][Full Text] [Related]
32. Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline.
Gourmaud S; Paquet C; Dumurgier J; Pace C; Bouras C; Gray F; Laplanche JL; Meurs EF; Mouton-Liger F; Hugon J
J Psychiatry Neurosci; 2015 May; 40(3):151-61. PubMed ID: 25455349
[TBL] [Abstract][Full Text] [Related]
33. Recent advances of small molecule JNK3 inhibitors for Alzheimer's disease.
Qin P; Ran Y; Liu Y; Wei C; Luan X; Niu H; Peng J; Sun J; Wu J
Bioorg Chem; 2022 Nov; 128():106090. PubMed ID: 35964505
[TBL] [Abstract][Full Text] [Related]
34. JNK3 mediates paraquat- and rotenone-induced dopaminergic neuron death.
Choi WS; Abel G; Klintworth H; Flavell RA; Xia Z
J Neuropathol Exp Neurol; 2010 May; 69(5):511-20. PubMed ID: 20418776
[TBL] [Abstract][Full Text] [Related]
35. Discovery of novel imidazole chemotypes as isoform-selective JNK3 inhibitors for the treatment of Alzheimer's disease.
Jun J; Yang S; Lee J; Moon H; Kim J; Jung H; Im D; Oh Y; Jang M; Cho H; Baek J; Kim H; Kang D; Bae H; Tak C; Hwang K; Kwon H; Kim H; Hah JM
Eur J Med Chem; 2023 Jan; 245(Pt 1):114894. PubMed ID: 36343411
[TBL] [Abstract][Full Text] [Related]
36. A Perspective on the Development of c-Jun N-terminal Kinase Inhibitors as Therapeutics for Alzheimer's Disease: Investigating Structure through Docking Studies.
Cho H; Hah JM
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680547
[TBL] [Abstract][Full Text] [Related]
37. Characterisation of de novo MAPK10/JNK3 truncation mutations associated with cognitive disorders in two unrelated patients.
Kunde SA; Rademacher N; Tzschach A; Wiedersberg E; Ullmann R; Kalscheuer VM; Shoichet SA
Hum Genet; 2013 Apr; 132(4):461-71. PubMed ID: 23329067
[TBL] [Abstract][Full Text] [Related]
38. c-Jun N-terminal kinases 3 (JNK3) from orange-spotted grouper, Epinephelus coioides, inhibiting the replication of Singapore grouper iridovirus (SGIV) and SGIV-induced apoptosis.
Guo M; Wei J; Zhou Y; Qin Q
Dev Comp Immunol; 2016 Dec; 65():169-181. PubMed ID: 27422159
[TBL] [Abstract][Full Text] [Related]
39. c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia.
Waetzig V; Czeloth K; Hidding U; Mielke K; Kanzow M; Brecht S; Goetz M; Lucius R; Herdegen T; Hanisch UK
Glia; 2005 May; 50(3):235-46. PubMed ID: 15739188
[TBL] [Abstract][Full Text] [Related]
40. Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors.
Zhao H; Serby MD; Xin Z; Szczepankiewicz BG; Liu M; Kosogof C; Liu B; Nelson LT; Johnson EF; Wang S; Pederson T; Gum RJ; Clampit JE; Haasch DL; Abad-Zapatero C; Fry EH; Rondinone C; Trevillyan JM; Sham HL; Liu G
J Med Chem; 2006 Jul; 49(15):4455-8. PubMed ID: 16854050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
